Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd

This early-stage study is testing the safety and initial effects of a new drug called SYN818 when given with an existing cancer drug, olaparib. It is for adults with advanced or metastatic solid tumors (like ovarian or breast cancer) that have specific genetic changes (BRCA mutat…